Vaxcyte, Inc.
Company Information
Industry
Biological Products, (No Diagnostic Substances)
SIC Code
2836
Entity Type
operating
SEC Category
Large accelerated filer
State of Incorporation
DE
Business Address
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA, 94070
Mailing Address
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA, 94070
Phone
650-837-0111
Fiscal Year End
1231
EIN
464233385
Financial Overview
FY2025
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 27, 2026 | View on SEC |
| 4 Insider stock transaction report | March 18, 2026 | View on SEC |
| 4 Insider stock transaction report | March 11, 2026 | View on SEC |
| 4 Insider stock transaction report | March 11, 2026 | View on SEC |
| 4 Insider stock transaction report | March 11, 2026 | View on SEC |
| 4 Insider stock transaction report | March 11, 2026 | View on SEC |
| 4 Insider stock transaction report | March 11, 2026 | View on SEC |
| 4 Insider stock transaction report | March 2, 2026 | View on SEC |
| 4 Insider stock transaction report | March 2, 2026 | View on SEC |
| 4 Insider stock transaction report | March 2, 2026 | View on SEC |
Annual Reports
10-K
February 24, 2026
- VAX-24 successfully completed Phase 2 clinical trials and is on track to start a pivotal Phase 3 trial in Q3 2026.
- Vaxcyte ended 2025 with a robust cash position of approximately $650 million, providing operational runway into late 2027.
Insider Trading
STRONG SELL
3 insiders
8 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2836)
Scinai Immunotherapeutics Ltd.
SCNI
Biological Products, (No Diagnostic Substances)
Genenta Science S.p.A.
GNTA
Biological Products, (No Diagnostic Substances)
Greenland Mines Ltd
GRML
Biological Products, (No Diagnostic Substances)
Kymera Therapeutics, Inc.
KYMR
Biological Products, (No Diagnostic Substances)
Innate Pharma SA
IPHA
Biological Products, (No Diagnostic Substances)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.